To date, drugs developed to treat patients with EGFR-vIII or EGFR have proven to be ineffective due to the inability of such drugs to overcome the BBB, to tumor heterogeneity, and to the activation of compensatory pathways such as Src [21,22,23,24]. Here, EGFR is linked to neoplasm.